TY - JOUR
T1 - Characterization of blood-derived exosomal hTERT mRNA as a biomarker for colon cancer and Lynch syndrome
AU - Laish, Ido
AU - Levi, Zohar
AU - Mahajna, Hussein
AU - Albshesh, Ahmad
AU - Horesh, Nir
AU - Katz, Efraim
AU - Feldman, Dan
AU - Shinar, Nadav
AU - Picard, Orit
AU - Yavzori, Miri
AU - Fudim, Ella
AU - Raanani, Pia
AU - Berger, Tamar
AU - Goldvaser, Hadar
AU - Beery, Einat
AU - Uziel, Orit
N1 - Publisher Copyright:
Copyright © 2022 Laish, Levi, Mahajna, Albshesh, Horesh, Katz, Feldman, Shinar, Picard, Yavzori, Fudim, Raanani, Berger, Goldvaser, Beery and Uziel.
PY - 2022/9/20
Y1 - 2022/9/20
N2 - Background: Human telomerase reverse transcriptase (hTERT)- mRNA was shown to be elevated in exosomes derived from the sera of a variety of hematological and solid cancer patients. We aimed to evaluate its role as a diagnostic marker in patients with newly diagnosed colon cancer and in hereditary syndromes with predisposition to colon cancer. Methods: hTERT -mRNA levels were determined in serum-derived exosomes from 88 patients with colon cancer, 71 Lynch-syndrome carriers with unknown active malignancies and 50 healthy controls. Data, including demographics, background diseases, clinical data regarding tumor characteristics and genetic data, were retrieved data from medical files. Results: Patients with colon cancer had both higher exosomal hTERT mRNA levels and a higher proportion of patients with positive exosomal hTERT mRNA than controls (29.5% vs. 4%, respectively, P values < 0.001). Within the cancer group, patients with a metastatic disease had higher levels of telomerase mRNA than non-metastatic disease patients, and these levels correlated with CEA levels. Likewise, Lynch syndrome carriers had a higher proportion of positive exosomal hTERT mRNA than controls (21.1% vs. 4%, respectively, P value 0.008) but only a trend towards higher exosomal hTERT mRNA levels. Higher telomerase mRNA levels were not correlated with the mutated gene. Conclusions: Exosomal serum hTERT –mRNA levels are associated with metastatic colon cancer and were also demonstrated in a subset of Lynch syndrome carriers. Its significance as a biomarker for developing malignancy should be elucidated.
AB - Background: Human telomerase reverse transcriptase (hTERT)- mRNA was shown to be elevated in exosomes derived from the sera of a variety of hematological and solid cancer patients. We aimed to evaluate its role as a diagnostic marker in patients with newly diagnosed colon cancer and in hereditary syndromes with predisposition to colon cancer. Methods: hTERT -mRNA levels were determined in serum-derived exosomes from 88 patients with colon cancer, 71 Lynch-syndrome carriers with unknown active malignancies and 50 healthy controls. Data, including demographics, background diseases, clinical data regarding tumor characteristics and genetic data, were retrieved data from medical files. Results: Patients with colon cancer had both higher exosomal hTERT mRNA levels and a higher proportion of patients with positive exosomal hTERT mRNA than controls (29.5% vs. 4%, respectively, P values < 0.001). Within the cancer group, patients with a metastatic disease had higher levels of telomerase mRNA than non-metastatic disease patients, and these levels correlated with CEA levels. Likewise, Lynch syndrome carriers had a higher proportion of positive exosomal hTERT mRNA than controls (21.1% vs. 4%, respectively, P value 0.008) but only a trend towards higher exosomal hTERT mRNA levels. Higher telomerase mRNA levels were not correlated with the mutated gene. Conclusions: Exosomal serum hTERT –mRNA levels are associated with metastatic colon cancer and were also demonstrated in a subset of Lynch syndrome carriers. Its significance as a biomarker for developing malignancy should be elucidated.
KW - Lynch syndrome
KW - colon cancer
KW - exosomes
KW - genetic syndromes
KW - telomerases
UR - http://www.scopus.com/inward/record.url?scp=85139183669&partnerID=8YFLogxK
U2 - 10.3389/fonc.2022.962473
DO - 10.3389/fonc.2022.962473
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 36203446
AN - SCOPUS:85139183669
SN - 2234-943X
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 962473
ER -